PMID: 16524074Mar 10, 2006Paper

Hematopoietic stem cell transplant in combined immunodeficiency syndromes of childhood: an optimal treatment for primary immunodeficiency

Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
Alberto Olaya-VargasDoris Lormendez-Jacome

Abstract

The congenital immunodeficiency disorders in which the defect has been clearly traced to the stem cell can be cured with allogeneic stem-cell transplantation (SCT) from an unaffected donor. Widespread application of this treatment modality has been tempered by the fact that risk-benefit considerations do not always favor a procedure that carries a significant risk for morbidity and mortality. Some malignant disorders of childhood eventually have to be treated by an autologous or allogeneic SCT, however nonmalignant disorders can also be treated with this approach. This article reviews the current status of SCT for nonmalignant inherited immunodeficiency disorders.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
P DregerNorbert Schmitz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Katharine BransonStephen Mackinnon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
K Scott BakerLeslie L Robison
© 2021 Meta ULC. All rights reserved